Latest Sales Growth News

Briscoe Group Limited reported record full-year sales of NZD 798.8 million for FY2026, with net profit after tax dipping slightly to NZD 59.2 million. The company maintained dividends and invested heavily in supply chain upgrades despite a challenging retail environment.

HighCom Limited has successfully raised nearly $800,000 through a Share Purchase Plan, adding to a prior $7 million placement to fund product upgrades and sales growth.

Control Bionics has secured a key regulatory milestone with its NeuroNode device now eligible for reimbursement under Germany’s statutory health insurance, paving the way for expanded European distribution.

Endeavour Group reported a solid first half for fiscal 2026 with underlying EBIT of $563 million, supported by retail price leadership and strong hotel sales growth. The group raised capital expenditure guidance, reflecting accelerated hotel renewals and strategic investments.

Eden Innovations Ltd reports a $1.43 million half-year profit, reversing prior losses thanks to a $4.45 million property sale and significant debt reduction, while advancing international commercialisation of its concrete and fuel technologies.

Osteopore Limited reported an 11% increase in revenue to $3.06 million for 2025, alongside a wider net loss of $3.72 million as it invests heavily in product development and regulatory compliance. The company also expanded its footprint with a new Singapore subsidiary.

SDI Limited reported a modest 2% dip in net profit for H1 FY26 despite a 2.7% rise in sales, driven by growth in aesthetics and exports. The company faces challenges from regulatory bans on Amalgam products while advancing plans for manufacturing upgrades and a potential acquisition.

Michael Hill International reported a 3% rise in group sales and a 28.6% jump in comparable EBIT for the half-year ended December 2025, driven by strong performances across Australia, Canada, and New Zealand. Despite improved earnings and cash flow, the board has opted to withhold an interim dividend, signalling cautious optimism.

Botanix Pharmaceuticals reports a surge in Sofdra sales driving revenue to $16.5 million, yet the company records a $33.2 million loss amid expanded marketing and operational costs. A $45 million capital raise aims to support growth and supply chain improvements.

Harvey Norman Holdings Limited reported a robust 6.9% rise in system sales revenue for 1H26, underpinned by strong Australian franchisee performance and overseas expansion. Profit before tax climbed 16.5%, boosted by property revaluations and disciplined cost management.

Freehill Mining Limited has secured options to acquire a portfolio of promising copper-gold projects in Chile, including a JORC-compliant resource at Blanco y Negro and extensive exploration potential at Joshua and Samuel. The deal features low upfront payments and milestone-based future costs, aligning with Freehill’s growth strategy supported by its cash-generating aggregates business.

Coles Group reported a 2.5% revenue increase to $23.7 billion for the half year ended January 2026, driven by strong supermarket sales, but earnings were weighed down by a $235 million provision linked to a Fair Work Ombudsman ruling. The company declared a fully franked interim dividend of 41 cents per share.